Q-omics provides the consensus-scored PCYT1B profile across patient tissues and cancer cell-line models. PCYT1B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PCYT1B is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, PCYT1B RNA expression shows 19,956 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LUAD, and LSCC as cancer lineages where PCYT1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCYT1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCYT1B survival associations across molecular data types. PCYT1B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCYT1B RNA expression–survival associations across cancer types. High PCYT1B expression shows unfavorable associations in BLCA, STAD, THCA and LIHC, but favorable associations in ACC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PCYT1B RNA expression.
This table summarizes PCYT1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PCYT1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCYT1B shows lower tumor expression in LUAD, KICH, BRCA, COAD and KIRP and higher tumor expression in HNSC. The LUAD box plot shows higher PCYT1B RNA expression in normal versus tumor tissue (log2 FC = −1.285, t-test p < 0.001).
This table shows molecular features associated with PCYT1B in patient tissues and cancer cell lines. In patient samples, PCYT1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCYT1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
